Prescription for Change 2025

46. The Message Project. (2024, November). MESSAGE policy framework. https://www.messageproject.co.uk/wp-content/ uploads/2024/11/MESSAGE-Policy- 47. Hutchison, K. (2020, January 1). Gender bias in medical implant design and use: A type of moral aggregation problem? Hypatia, 34(3), 570–591. https://doi.org/10.1111/hypa.12483 48. National Institutes of Health Office of Research on Women’s Health. (2024, April 16). Sex as a biological variable. https://orwh.od.nih.gov/sex-as-biological-variable 49. University of Maryland School of Pharmacy. (n.d.). The PATIENTS Professors Academy. Retrieved April 4, 2025, from https://www.pharmacy.umaryland.edu/programs/the-patients-program/patients-academy/ 50. Wells, K. E., Peterson, E. L., Ahmedani, B. K., Severson, R. K., Gleason-Comstock, J., & Williams, L. K. (2012). The relationship between combination inhaled corticosteroid and long-acting -agonist use and severe asthma exacerbations in a diverse population. The Journal of Allergy and Clinical Immunology, 129(5), 1274–1279.e2. https://pmc.ncbi.nlm.nih. gov/articles/PMC3340459/ 51. Heidari, S., Babor, T. F., De Castro, P ., Tort, S., & Curro, M. (2016). Sex and gender equity in research: Rationale for the SAGER guidelines and recommended use. Research Integrity and Peer Review, 1, 2. https://doi.org/10.1186/s41073- 016-0007-6 52. Region Stockholm. (n.d.). Janusmed sex and gender. Janusinfo. Retrieved April 4, 2025, from https://janusmed.se/en/ sexandgender Prescription for Change: Policy Recommendations for Women’s Health Research 27